GCC 0901- A Phase II Study of Letrozole in Combination With Lapatinib Followed by an Addition of Everolimus in Postmenopausal Women With Advanced Endocrine Resistant Breast Cancer.

Trial Profile

GCC 0901- A Phase II Study of Letrozole in Combination With Lapatinib Followed by an Addition of Everolimus in Postmenopausal Women With Advanced Endocrine Resistant Breast Cancer.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 09 Mar 2016

At a glance

  • Drugs Everolimus (Primary) ; Lapatinib (Primary) ; Letrozole (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 Mar 2016 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 25 Jan 2015 Planned primary completion date changed to 1 Nov 2014, according to ClinicalTrials.gov record.
    • 25 Jan 2015 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top